February 10, 2017 — Independent market research consultancy Robust Insight recently conveyed a survey commissioned by IBA on the state of the proton therapy market entering 2017. The report is based on an online survey among 1,200 hospitals in order to assess how they view proton therapy today and in the future.
Two hundred twenty-two replies from professionals in radiation oncology were received from 205 institutions in 29 countries. Thirty-six percent of the respondents were from centers performing proton therapy. The main highlights of the study are:

Sixty-eight percent of respondents believe that proton therapy will continue to grow rapidly in the future;

Eighty-two percent of respondents were aware that proton therapy has lower risk of treatment-induced disorders versus conventional radiation therapy;

Compared to a similar study in 2009, proton therapy is seen as more efficacious in 2016 than in 2009 for cancers like pediatric, base-of-skull treatment, lung and prostate;

Just over 50 percent of the respondents cite limited clinical evidence and limited reimbursement for proton therapy as the biggest barriers impacting the growth of the field;

Seventy-seven percent of respondents believe there will be more and more clinical evidence demonstrating the benefits of proton therapy; and

Seventy-three percent believe that the availability of proton therapy will have a growing impact on centers’ reputation.

For more information: www.robust-insight.co.uk

Rad Oncology Homepage